NLRP4 and pancreatic neoplasm: This study provides evidence that NLRP4, a constituent of the nucleotide-binding and oligomerization domain-like receptor (NLR) family, imparts resistance to olaparib in pancreatic cancer cells, both in vitro and in vivo.